Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

Stock Information for Inhibikase Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inhibikase Therapeutics Inc.

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.